Abbott Laboratories (ABT) said Sunday its investigational, leadless Aveir Conduction System Pacing device showed safety and performance in a clinical feasibility study.

The device delivers conduction pacing to the heart's left bundle branch area by mimicking the heart's electrical rhythm, the company said.

Abbott also recently started enrolling patients in a clinical trial of up to 414 people to evaluate the safety and effectiveness of its investigational CSP Implantable Cardioverter-Defibrillator lead.

The US Food and Drug Administration recently granted breakthrough device designations to both the Aveir and CSP devices, the company said.